Ann: Scheme Update, page-3

No Waiver of Qualifying Confirmatory Data Readout Condition

ResApp has received confirmation from Pfizer that it will not waive the Qualifying Confirmatory Data Condition, confirming the Scheme Consideration of A$0.146 per ResApp share in cash, representing an equity value of A$127 million.

So they are sticking to the low ball offer. Seems a bit hit and hope to me. I am pretty sure that 14.6 is going to get voted down.